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S U M M A R Y
Background: Viral infections are a major cause of morbidity and mortality after hematopoietic stem cell
transplantation (HSCT). The effect of herpesvirus infections in human cytomegalovirus (HCMV)-
seropositive (IgG-positive/IgM-negative) HSCT recipients remains poorly understood. The risk factors
associated with Epstein–Barr virus (EBV), HCMV, and human herpes virus type 6 (HHV-6) infections after
HSCT, both alone and in combination, were investigated in this study.
Methods: Peripheral blood specimens were collected from 44 HSCT recipients and examined for viral
DNA using quantitative ﬂuorescence PCR assays. Risk factors for EBV, HCMV, and HHV-6 infections were
analyzed by binary logistic regression, and relationships between these viruses were analyzed using the
Chi-square test.
Results: EBV, HCMV, and HHV-6 were detected in 50%, 45.45%, and 25% of HCMV-seropositive (IgG-
positive/IgM-negative) HSCT recipients, respectively. Male sex (p = 0.007) and conditioning regimens
including anti-thymocyte globulin (ATG) (p = 0.034) were strongly associated with an increased risk of
EBV infection. Graft-versus-host disease (GVHD) prophylaxis with corticosteroids was a risk factor for
both EBV (p = 0.013) and HCMV (p = 0.040) infections, while EBV infection (p = 0.029) was found to be an
independent risk factor for HHV-6 infection. Pre-existing HHV-6 infection was associated with lower
rates of HCMV infection (p = 0.002); similarly, pre-existing HCMV infection was protective against HHV-
6 infection (p = 0.036).
Conclusions: HCMV-seropositive (IgG-positive/IgM-negative) HSCT recipients exhibited a high rate of
herpesvirus infections, particularly EBV. ATG and male sex were strongly associated with an increased
risk of EBV infection. GVHD prophylaxis with prednisone was found to affect both EBV and HCMV
infections. Prior infection with EBV was shown to promote HHV-6 infection. Taken together, these data
highlight the need for active monitoring of herpesvirus infections in patients undergoing HSCT.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Hematopoietic stem cell transplantation (HSCT) has proven
to be an effective measure in the treatment of hematological
malignancies. However, this procedure is not without signiﬁcant
risks, particularly that of viral infections, which remain one of
the major causes of morbidity and mortality after HSCT.1,2
Transplantation is often accompanied by the use of potent* Corresponding author. Tel.: +86 571 87236581; fax: +86 571 87236444.
E-mail address: hjianhua0825@126.com (J. Hu).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).immunosuppressive drugs to both prevent and treat graft-
versus-host disease (GVHD). The use of these drugs results in a
severely compromised immune system, making HSCT patients
more vulnerable to primary viral infections and reactivation.
Herpesviruses are among the most common opportunistic
viral infections in HSCT recipients. Of these infections, human
cytomegalovirus (HCMV) pneumonia and enteritis are the most
serious and often fatal complications, with a mortality rate
exceeding 50% after HSCT.3 Primary Epstein–Barr virus (EBV)
infection and lymphoproliferative disorders can occur after
T-cell-depleted HSCT,4 while human herpesvirus 6 (HHV-6),5 a
member of the b-herpesvirus family along with HCMV, can achieveciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Characteristics of the study patients
Characteristics of patients Value
Patients, n 44





Acute myelogenous leukemia 19 (43.20%)
Acute lymphoblastic leukemia 18 (40.90%)
Non-Hodgkin lymphoma 1 (2.27%)
Myelodysplastic syndrome 5 (11.36%)
Lymphosarcoma cell leukemia 1 (2.27%)
Conditioning regimen
Ara-c + BUCY + MeCCNU + ATG 21 (47.73%)
Ara-C + BUCY + MeCCNU 4 (9.09%)
BUCY + ATG + MeCCNU 5 (11.36%)
Ara-C + BUCY + ATG 1 (2.27%)
BUCY + MeCCNU 11 (25.00%)
BUCY + ATG 1 (2.27%)
BUCY 1 (2.27%)
Type of donor
HLA-identical sibling 16 (36.36%)
Mismatched related donor 14 (31.82%)
Matched unrelated donor 11 (25.0%)
Mismatched unrelated donor 3 (6.82%)
Stem cell source
Peripheral blood 42 (95.45%)
Peripheral blood and bone marrow 2 (4.55%)
GVHD prophylaxis
Mycophenolate mofetil + cyclosporine 10 (22.73%)
Mycophenolate mofetil + cyclosporine + prednisone 34 (77.27%)
aGVHD
Grade 0–I 36 (81.82%)
Grade II–IV 8 (13.64%)
Deatha 5 (11.36%)
Pulmonary fungal infection 2 (4.55%)
Pulmonary hemorrhage 1 (2.27%)
Hemorrhage of digestive tract 1 (2.27%)
Pulmonary fungal infection and hemorrhage of digestive tract 1 (2.27%)
Ara-C, cytosine arabinoside; BU, busulfan; CY, cyclophosphamide; MeCCNU,
methylcyclohexylnitrosamine; ATG, anti-thymocyte globulin; HLA, human leukocyte
antigen; GVHD, graft-versus-host disease; aGVHD, acute graft-versus-host disease.
a Death: these deaths had no direct correlation with the viral infections.
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after HSCT has been associated with a variety of symptoms
including skin rash, fever, interstitial pneumonitis, bone marrow
suppression, encephalitis, and GVHD.6–9
The vast majority of research into herpesvirus infections in
HSCT recipients has focused on HCMV, with very little known
regarding either EBV or HHV-6. Moreover, few studies have
examined the effects of these viruses in combination, particularly
in the context of HCMV-seropositive (IgG-positive/IgM-negative)
HSCT recipients. In previous studies examining the relationships
between the herpesviruses, b-herpesviruses were found to
transactivate each other, while HCMV infection appeared to
trigger HHV-6 and/or HHV-7 co-infection and vice versa.10
However, the relationship between EBV and b-herpesvirus
infections remains poorly understood. In this study, HSCT
recipients who were seropositive for HCMV (IgG-positive/IgM-
negative) before transplantation were examined to assess the
relationships between HCMV, EBV, and HHV-6 infections after
HSCT and to identify potential risk factors for viral infection.
2. Methods
2.1. Human subjects and samples
HSCT recipients treated at the study hospital between January
2012 and June 2012 were tested for seropositivity (IgG and IgM) to
HCMV prior to transplantation; almost all of the patients were
infected with HCMV before transplantation. Following the exclu-
sion of the few HCMV IgG-negative patients, 44 patients with IgG-
positive/IgM-negative HCMV were enrolled in this study. Detailed
demographic and clinical data for these patients are shown in
Table 1. Plasma samples were collected once weekly in the ﬁrst
month, twice in the second and third months after transplantation,
and then every 1–2 months until December 2012 (range 3 months
to 1 year). In total, 392 peripheral blood specimens (range 5–17
samples per patient) were collected, from which peripheral blood
leukocytes (PBLs) were isolated and stored at 70 8C until DNA
extraction. For some patients, the number of follow-up samples
was limited due to early death or loss to follow-up.
2.2. Conditioning regimen and post-transplant treatment
HSCT recipients were treated with or without anti-thymocyte
globulin (ATG) before transplantation. Patients were treated with
mycophenolate mofetil plus cyclosporine in combination with
short-term methotrexate and intravenous ganciclovir (5 mg/kg per
day) for HCMV, for 7 days prior to transplantation. This was followed
by long-term mycophenolate mofetil plus cyclosporine and
prednisone, or mycophenolate mofetil plus cyclosporine for GVHD
prophylaxis, sulfamethoxazole for Pneumocystis carinii pneumonia
(4 tablets, twice daily), and intravenous ganciclovir for HCMV (5 mg/
kg per day for the ﬁrst 2 weeks) after transplantation. Acute GVHD
and chronic GVHD were diagnosed and graded according to
standard criteria.11 Corticosteroids were used in patients with
grade II–IV acute GVHD, with varying durations.
2.3. DNA detection of herpesviruses
2.3.1. Primers and probes
Herpesvirus DNA was extracted using a commercial DNA
extraction kit (Promega Biological Technology Co. Ltd, Beijing,
China) in accordance with the manufacturer’s instructions. The
primers and probes used to detect EBV, HCMV, and HHV-6 have
been described previously.4,12,13 Brieﬂy, PCR primers and probes
for EBV were selected from BALF5,4 those for HCMV from the
immediate early (IE) gene,13 and those for HHV-6 from the U31gene.12 All primers and probes were synthesized by ZeHeng
Technology (Shanghai, China).
2.3.2. Quantitative ﬂuorescence PCR assay
Quantitative ﬂuorescence PCR was performed using a TaqMan
PCR Kit (Takara, Dalian, China) and run on an ABI 7500 Real-Time
PCR System (USA), as described previously.3 Standard strains were
used as positive controls in each ampliﬁcation (B95-8 for EBV,
AD169 for CMV, and GS for HHV-6A). In addition to a blank control,
distilled water was used as a negative control. Real-time
ﬂuorescence was measured, and cycle threshold (Ct) values were
calculated for each sample .
Speciﬁcity was conﬁrmed using viral DNA from standard strains.
Sensitivity was conﬁrmed by TaqMan Qualitative ﬂuorescence PCR
using serial dilutions of standard strains, with a minimum detectable
Ct value of 48 relative to undiluted samples, which produced Ct
values of 16. No peaks were detected in the negative control.
2.4. Statistical analyses
All statistical analyses were performed using SPSS version 16.0
(SPSS Inc., Chicago, IL, USA). Qualitative variables, such as the
clinical characteristics of the HSCT recipients, were recorded as the
percentage of the positive results, and differences in these
variables were evaluated using the Chi-square test. Quantitative
variables, such as age, were recorded as the median and range. Risk
Table 2
Herpesvirus infections after HSCT
Virus Patients Ct value Time to
infection, days
Median Range Median Range
EBV 22 (50%) 35.42 31.04–38.67 45 14–88
HCMV 20 (45.45%) 23.90 17.96–27.42 32 11–76
HHV-6 11 (25%) 35.00 30.90–37.44 39 24–87
EBV + HCMV 10 (22.73%)
EBV + HHV-6 6 (13.64%)
HCMV + HHV-6 0 (0%)
EBV + HCMV + HHV-6 2 (4.55%)
HSCT, hematopoietic stem cell transplantation; Ct, cycle threshold; EBV, Epstein–
Barr virus; HCMV, human cytomegalovirus; HHV-6, human herpes virus type 6.
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logistic regression. The results were expressed as the odds ratio
(OR) with corresponding 95% conﬁdence interval (CI). A p-value of
<0.05 was considered statistically signiﬁcant.
3. Results
The aim was to examine HCMV, EBV, and HHV-6 viral
infections, the risk factors for infection, and their relationships
in HSCT recipients. The Ct value can reﬂect the concentration of
virus. As the Ct value was considered sufﬁcient for the purposes of
this research, the quantitation of standard strains was not
performed. Serial dilutions of standard strains detected in the
study were used to verify the validity of PCR and the relative
detection range, in order to ensure the reliability of the PCR. The
aim when obtaining multiple specimens for an objective is to
observe the change in viruses over a period of time. As the overall
relationship of the three virus infections was analyzed in this
study, the use of the median Ct value was considered sufﬁcient for
this purpose and not to have any inﬂuence on the analysis. The use
of the Ct value to determine expression has been reported
previously in the literature.14
3.1. Herpesvirus infections
The ﬁrst sample was collected from each patient during the ﬁrst
week after transplantation. These ﬁrst patient samples were all
PCR-negative for the viruses. Among the 44 HCMV-seropositive
(IgG-positive/IgM-negative) HSCT recipients included in this
study, 22 (50%) tested positive for EBV after transplantation at a
median Ct value of 35.42 (range 31.04 to 38.67 cycles). The median
time to EBV DNA detection was 45 days post-transplantation
(range 14–88 days). Twenty patients (45.45%) tested positive for
HCMV at a median Ct value of 23.90 (range 17.96 to 27.42 cycles).
The median time to HCMV DNA detection was 32 days post-
transplantation (range 11–76 days). Eleven patients (25%) tested
positive for HHV-6 at a median Ct value of 35.00 (range 30.90–
37.44 cycles). The median time to HHV-6 DNA detection was
39 days post-transplantation (range 24–87 days) (Table 2 ). Co-
infections were observed in 18 patients. Ten patients (22.73%)
were co-infected with EBV and HCMV, of whom ﬁve tested positive
for EBV ﬁrst, four for HCMV ﬁrst, and one for both simultaneously.
Six patients (13.64%) were co-infected with EBV and HHV-6, of
whom three tested positive for EBV ﬁrst, one for HHV-6 ﬁrst, and
two for both infections at the same time. Finally, two patients
(4.55%) were co-infected with all three viruses, both of whom
tested positive for HCMV, then EBV, and ﬁnally HHV-6 (Table 2).
3.2. Risk factors for EBV, HCMV, and HHV-6 infections after HSCT
Potential risk factors for EBV, HCMV, and HHV-6 infections in
HSCT recipients were analyzed using binary logistic regres-
sion.3,10,12,15–18 Male patients were 13.24 times more susceptible
to EBV infection than female patients (p = 0.007). Conditioning
regimens that included ATG (OR 7.690, p = 0.034) and GVHDTable 3
Binary logistic analysis for EBV, HCMV, and HHV-6 risk factors
Virus Factors 
EBV Male donor 
GVHD prophylaxis including corticosteroids 
ATG included in conditioning regimen 
HCMV GVHD prophylaxis including corticosteroids 
HHV-6 EBV infection 
EBV, Epstein–Barr virus; HCMV, human cytomegalovirus; HHV-6, human herpes virus ty
anti-thymocyte globulin.prophylaxis regimens that included prednisone (OR 23.681,
p = 0.013) were also strongly associated with an increased risk
of EBV infection. Similarly, GVHD prophylaxis regimens that
included prednisone (OR 13.565, p = 0.040) were also signiﬁcantly
associated with an increased risk of HCMV infection. EBV infection
(OR 6.726, p = 0.029) was identiﬁed as an independent risk factor
for HHV-6 infection (Table 3). Other potential risk factors, such as a
sex mismatch between the donor and recipient, ABO blood type
mismatch, human leukocyte antigen (HLA) mismatches, etc. were
found not to be risk factors for EBV, HCMV, and HHV-6 infections.
3.3. Relationships between EBV, HCMV, and HHV-6 infections after
HSCT
Prior to EBV detection, 15 patients were already infected with
HCMV and six with HHV-6; seropositivity for both of these
infections did not affect EBV infection (p = 0.750, p = 1.000). Among
the HCMV-infected individuals, six were pre-infected with EBV
and nine were pre-infected with HHV-6. EBV status did not affect
the infection rate, while HHV-6 pre-infection was associated with a
signiﬁcantly lower rate of HCMV infection (p = 0.002). Finally,
among the HHV-6-infected patients, seven were pre-infected with
EBV and two with HCMV. HCMV pre-infection was also found to be
a protective factor for HHV-6 infection (p = 0.036); no effect was
seen for EBV. The relationships between EBV, HCMV, and HHV-6
infection rates in HSCT recipients are shown in Table 4.
4. Discussion
HCMV is one of the most common human pathogens, with
seroprevalence ranging from 40% to 100%.19 Despite its prevalence,
little is known of its co-occurrence with other common viruses
such as EBV and HHV-6, particularly in the context of HCMV-
seropositive HSCT recipients. In this study, HSCT recipients who
were seropositive for HCMV (IgG-positive/IgM-negative) before
HSCT were examined. The rate of HCMV infection after HSCT was
45.45% (20 patients), a rate similar to that seen in previous
studies.15,20 Immunosuppressive drug regimens put transplant
recipients at a higher risk of EBV infection, which often manifests
in the form of post-transplantation lymphoproliferative disease.21Coefﬁcient (B) OR (95% CI) p-Value
2.583 13.240 (2.006–87.387) 0.007
3.165 23.681 (1.924–291.449) 0.013
2.040 7.690 (1.171–50.493) 0.034
2.607 13.565 (1.125–163.496) 0.040
1.906 6.726 (1.213–37.303) 0.029
pe 6; OR, odds ratio; CI, conﬁdence interval; GVHD, graft-versus-host disease; ATG,
Table 4
Relationships of EBV, HCMV, and HHV-6 infections
Total EBV infection Total HCMV infection Total HHV-6 infection
Number p-Value Number p-Value Number p-Value
Total 44 22 44 20 44 11
EBV pre-infection 0.423 0.223
Yes 16 6 21 7
No 28 14 23 4
HCMV pre-infection 0.750 0.036
Yes 15 7 20 2
No 29 15 24 9
HHV-6 pre-infection 1.000 0.002
Yes 6 3 9 0
No 41 19 35 20
EBV, Epstein–Barr virus; HCMV, human cytomegalovirus; HHV-6, human herpes virus type 6.
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similar to those in other reports.16,17
HHV-6 and HCMV are closely related members of the b-
herpesvirus family and share many characteristics. Zerr et al.
reported that more than 90% of the population are infected with
HHV-6 within the ﬁrst 18 months of life.6 Among the 44 patients
included in this study, 25% (11 patients) tested positive for HHV-6
DNA in their PBLs, a much lower rate than reported for the two
viruses described above. These observations are similar to those of a
previous report,16 although considerable variation is seen in the
literature.1,7,17 When comparing the studies, it is important to note
that the HSCT recipients in the present study were adults and
teenagers, with most being adults (81.82%), while the previously
reported HSCT recipients with higher HHV-6 infection rates were all
children.1,7,17 In addition, different sample types (e.g., whole blood
samples, plasma, or PBLs) and the lack of internationally standard-
ized PCR assays are likely to account for some of the discrepancies in
HHV-6 infection rates. The three herpesviruses described here were
all detected within the ﬁrst 3 months post-transplantation, with
HCMV infection occurring ﬁrst, followed by EBV and then HHV-6, a
pattern consistent with those seen in previous studies.5,16,17
Reported risk factors for EBV, HCMV, and HHV-6 after HSCT
include age, HLA mismatch, the presence of acute GVHD, ATG, and
GVHD prophylaxis regimens containing corticosteroids.3,10,12,15–18
In addition to these known risk factors, other potential risk factors
include the sex of the recipient and donor, sex mismatch between
the donor and recipient, ABO blood type mismatch, and other viral
infections.
It was found that GVHD prophylaxis regimens including
prednisone represented an independent risk factor for HCMV
infection, consistent with other studies.3,15 Immunosuppressed
patients exhibit delayed or reduced immune reconstitution, which
has been shown to have a direct effect on viral replication dynamics
in vivo;22 this effect may in turn affect HCMV replication. Close
monitoring for HCMV is therefore extremely important in patients
whose immunosuppression therapy includes corticosteroids.
In this study, the use of ATG in the conditioning regimen and
GVHD prophylaxis regimens containing corticosteroids were
associated with signiﬁcant increases in EBV infection post-
transplantation, with patients 7.7- to 23.7-times more likely to
become infected; this is similar to the ﬁndings of previous
studies.12,16–18 This effect is likely due to the action of ATG on
cellular immunity. As more than 90% of adults have been infected
with EBV, exposure to the virus is inevitable. After infection, EBV
persists within the body in resting memory B-cells, with cellular
immune responses controlling proliferating EBV-infected B-cells.
High-level immunosuppression, as achieved with ATG plus high-
dose corticosteroids, affects both the number and function of T-cells
to the point where existing T-cells may be unable to control EBV
proliferation, whether due to primary infection or reactivation.17
This model is also supported by the well-established mechanism ofaction of ATG in terms of in vivo partial T-cell depletion.18,23 The sex
of the donor was also found to be a signiﬁcant risk factor for EBV
infection, although the speciﬁc reasons underlying this effect
remain unknown.
GVHD, the administration of steroids for GVHD, and allele
mismatched donors have previously been associated with an
increased risk of active HHV-6 infection,7,10 although these
ﬁndings were not conﬁrmed in the present study. However, a
surprising ﬁnding was that EBV pre-infection facilitated HHV-6
infection thereafter (Table 3). This association may be due to
impaired T-cell immunity stemming from the GVHD prophylaxis
regimen, resulting in an immune system unable to suppress EBV
reactivation.17 EBV proliferation would further suppress T-
lymphocyte function and/or exhaust T-cells, enabling opportunis-
tic infections such as HHV-6. Alternatively, EBV proliferation may
induce the synthesis of proinﬂammatory cytokines and suppress
HHV-6-speciﬁc lymphoproliferative responses, triggering HHV-6
primary infection followed by proliferation and reactivation.
Different studies may identify different risk factors depending
on the target population, methods and samples used, etc. The risk
factors identiﬁed in the present study are just possibilities.
However, as potential risk factors, they are worthy of attention.
Despite the apparent associations observed between viral
infections, it is difﬁcult to determine whether these co-infections
represent new or reactivated infections, and what effects these
viruses may have on each other in vivo. Growing evidence suggests
that the b-herpesviruses are able to reversely activate other b-
herpesviruses due to their effects on immune regulation.10,24–29
However, Tormo et al. have argued against a role for HHV-6 in
promoting HCMV replication by inhibiting the reconstitution of
HCMV-speciﬁc T-cell immunity, which is consistent with the present
ﬁndings.10 Here, both HCMV and HHV-6 were found to decrease
susceptibility to the other virus. While the exact mechanism remains
unknown, it has been suggested that virus-speciﬁc IgG raised against
one virus may confer cross-immunity to the other, thereby
minimizing further infection. Alternatively, due to the strong
homology between HCMV and HHV-6, prior infection may confer
resistance due to competition for shared replication machinery.
Further research will be necessary to validate these hypotheses.
Few studies have examined the relationship between b-
herpesviruses and EBV. Aalto et al.30 and Razonable et al.31 have
suggested that HCMV infection may induce EBV infection and
proliferation. In this study, no relationship was found between
HCMV and EBV, or between HHV-6 and EBV, as analyzed by Chi-
square test (Table 4). However, EBV pre-infection was found to be
an independent risk factor for HHV-6 infection on binary logistic
regression analysis (Table 3). The exact pathophysiological basis
underlying this interaction is largely unknown, although it remains
possible that the immunosuppressive effects of the EBV system
may facilitate other infections such as HHV-6. Further research will
be necessary to validate this hypothesis.
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occurrence of EBV, HCMV, and HHV-6 in HCMV-seropositive (IgG-
positive/IgM-negative) HSCT recipients, with EBV being the most
common. Furthermore, these results conﬁrm the strong associa-
tion between T-cell depletion, male sex, and EBV reactivation.
GVHD prophylaxis regimens containing corticosteroids were
identiﬁed as a risk factor for both EBV and HCMV infections, with
each of the three viruses exhibiting some form of relationship.
HCMV and HHV-6 appear to serve as protective factors preventing
further infection, while EBV helps facilitate HHV-6 infection.
Some encouraging results were obtained and conclusions
drawn from this study, but there are some inevitable limitations.
First, the herpesvirus family includes a variety of viruses: herpes
simplex virus (HSV)-1, HSV-2, varicella zoster virus (VZV), HCMV,
EBV, HHV-6, HHV-7, and HHV-8. Unfortunately only three viruses
were investigated in this study (HCMV, EBV, and HHV-6). However,
this study will form part of a series of future studies on
herpesviruses, which will be performed step by step. A second
limitation was the use of Ct values; however, these were
considered sufﬁciently accurate for the purposes of this study
and not to have any inﬂuence on the analysis. Nevertheless it
would be better to report the number of copies of viral DNA to
demonstrate the change in virus infection. Third, the aim of this
study was to investigate virus infections in HSCT recipients who
were HCMV-seropositive (IgG-positive/IgM-negative) before
transplantation, while EBV and HHV-6 were not detected before
transplantation. This would not, therefore, allow us to determine
whether the infection that occurred later was a consequence of
reactivation or a primary infection. This should be clariﬁed in
future studies. Finally, the rate of HHV-6 infection is higher in
children than in adults.1,7,17 Whether younger adults have a higher
rate of infection should also be studied in the future.
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